Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

hypereosinophilic syndrome

- PMLiVE

AZ drug for opioid constipation clears phase III

Company hopes to file naloxegol in third quarter of 2013

UK flag

MRC funds UK research using 22 AstraZeneca compounds

Provides £7m for projects covering Alzheimer’s, cancer, lung disease and rare conditions

- PMLiVE

New CEO says AZ open to acquisitions to rebuild pipeline

Comments come as Q3 operating profit plummets 47 per cent

- PMLiVE

AstraZeneca signs IBS collaboration with Ironwood in China

Deal will also see Ironwood’s US sales force promote Nexium for gastroesophageal reflux disease

AZ’s MedImmune partners with global cancer institutes

Will research combinations of immunotherapies

- PMLiVE

AZ pays $273m for Ardelyx renal disease drug

Phase II candidate could tackle fluid overload in kidney and heart disorders

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

AstraZeneca and BGT shelve experimental sepsis drug

Decision follows CytoFab’s poor mid-stage clinical trial results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links